image
Healthcare - Medical - Devices - NASDAQ - US
$ 6.6
-2.37 %
$ 263 M
Market Cap
-4.58
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one LUNG stock under the worst case scenario is HIDDEN Compared to the current market price of 6.6 USD, Pulmonx Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one LUNG stock under the base case scenario is HIDDEN Compared to the current market price of 6.6 USD, Pulmonx Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one LUNG stock under the best case scenario is HIDDEN Compared to the current market price of 6.6 USD, Pulmonx Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart LUNG

image
$9.5$9.5$9.0$9.0$8.5$8.5$8.0$8.0$7.5$7.5$7.0$7.0$6.5$6.5$6.0$6.0$5.5$5.515 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
83.8 M REVENUE
22.01%
-57.7 M OPERATING INCOME
6.83%
-56.4 M NET INCOME
7.31%
-31.5 M OPERATING CASH FLOW
16.15%
17.5 M INVESTING CASH FLOW
970.75%
1.36 M FINANCING CASH FLOW
-93.63%
23.8 M REVENUE
16.57%
-15.1 M OPERATING INCOME
-7.11%
-13.2 M NET INCOME
6.85%
-6.73 M OPERATING CASH FLOW
7.07%
14.1 M INVESTING CASH FLOW
108.37%
62 K FINANCING CASH FLOW
-86.49%
Balance Sheet Pulmonx Corporation
image
Current Assets 136 M
Cash & Short-Term Investments 101 M
Receivables 13.1 M
Other Current Assets 21.6 M
Non-Current Assets 26.6 M
Long-Term Investments 0
PP&E 21.5 M
Other Non-Current Assets 5.15 M
62.32 %8.06 %13.29 %13.17 %3.16 %Total Assets$162.9m
Current Liabilities 24.4 M
Accounts Payable 3.83 M
Short-Term Debt 3.95 M
Other Current Liabilities 16.7 M
Non-Current Liabilities 52.6 M
Long-Term Debt 52.5 M
Other Non-Current Liabilities 87 K
4.97 %5.13 %21.62 %68.17 %Total Liabilities$77.0m
EFFICIENCY
Earnings Waterfall Pulmonx Corporation
image
Revenue 83.8 M
Cost Of Revenue 21.8 M
Gross Profit 62 M
Operating Expenses 120 M
Operating Income -57.7 M
Other Expenses -1.31 M
Net Income -56.4 M
100m100m80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)84m(22m)62m(120m)(58m)1m(56m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
74.00% GROSS MARGIN
74.00%
-68.87% OPERATING MARGIN
-68.87%
-67.30% NET MARGIN
-67.30%
-65.72% ROE
-65.72%
-34.63% ROA
-34.63%
-40.89% ROIC
-40.89%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Pulmonx Corporation
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)(50m)(50m)20192019202020202021202120222022202320232024202420252025
Net Income -56.4 M
Depreciation & Amortization 1.49 M
Capital Expenditures -1.45 M
Stock-Based Compensation 23 M
Change in Working Capital 0
Others 409 K
Free Cash Flow -33 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Pulmonx Corporation
image
Wall Street analysts predict an average 1-year price target for LUNG of $12.7 , with forecasts ranging from a low of $10 to a high of $16 .
LUNG Lowest Price Target Wall Street Target
10 USD 51.52%
LUNG Average Price Target Wall Street Target
12.7 USD 91.92%
LUNG Highest Price Target Wall Street Target
16 USD 142.42%
Price
Max Price Target
Min Price Target
Average Price Target
1616141412121010886644May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Pulmonx Corporation
image
Sold
0-3 MONTHS
1.13 M USD 5
3-6 MONTHS
223 K USD 3
6-9 MONTHS
361 K USD 3
9-12 MONTHS
94.6 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
97.4 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
EDAP Appoints Glen French to Board of Directors PDF Version LYON, France, March 3, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Glen French to its Board of Directors.          “We are pleased to welcome Glen to our Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS. globenewswire.com - 1 month ago
Pulmonx Corporation (LUNG) Q4 2024 Earnings Call Transcript Pulmonx Corporation (NASDAQ:LUNG ) Q4 2024 Results Conference Call February 19, 2025 4:30 PM ET Company Participants Elizabeth Sparicio - Investor Relations Steve Williamson - President and Chief Executive Officer Mehul Joshi - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Jon Young - Canaccord Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Joseph Downing - Piper Sandler Operator Ladies and gentlemen, thank you for standing by. Welcome to Pulmonx Fourth Quarter 2024 Earnings Conference Call. seekingalpha.com - 1 month ago
Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.36 per share a year ago. zacks.com - 1 month ago
Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. globenewswire.com - 1 month ago
Pulmonx to Present at the Citi 2025 Unplugged Medtech and Life Sciences Access Day REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Citi 2025 Unplugged Medtech and Life Sciences Access Day in New York on Thursday, February 27, 2025, at 8:00 AM PT / 11:00 AM ET. globenewswire.com - 2 months ago
Pulmonx to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025 REDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Wednesday, February 19, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. globenewswire.com - 2 months ago
Does Pulmonx (LUNG) Have the Potential to Rally 117.74% as Wall Street Analysts Expect? The consensus price target hints at an 117.7% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 4 months ago
Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York on Wednesday, December 4, 2024, at 9:30 AM PT / 12:30 PM ET. globenewswire.com - 4 months ago
Pulmonx Partners with American Lung Association to Launch New Educational Initiatives for COPD Patients and Providers REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, and the American Lung Association are continuing their ongoing collaboration with two new programs aimed at supporting patients with severe COPD and emphysema. Building on their successful partnership, the two organizations will launch new resources to educate patients and healthcare providers on innovative treatment options like the Ze. businesswire.com - 5 months ago
Pulmonx to Present at the Stifel 2024 Healthcare Conference REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Stifel 2024 Healthcare Conference in New York on Tuesday, November 19, 2024, at 6:10 AM PT / 9:10 AM ET. globenewswire.com - 5 months ago
Wall Street Analysts Predict an 89.61% Upside in Pulmonx (LUNG): Here's What You Should Know The average of price targets set by Wall Street analysts indicates a potential upside of 89.6% in Pulmonx (LUNG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com - 5 months ago
Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.39 per share a year ago. zacks.com - 5 months ago
8. Profile Summary

Pulmonx Corporation LUNG

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 263 M
Dividend Yield 0.00%
Description Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Contact 700 Chesapeake Drive, Redwood City, CA, 94063 https://pulmonx.com
IPO Date Oct. 1, 2020
Employees 291
Officers Mr. David A. Lehman J.D. General Counsel & Secretary Ms. Sarah Huber Vice President of Sales (U.S.) Ms. Lauren Cristina Vice President of Finance & Administration (U.S.) Mr. Steven S. Williamson Chief Executive Officer, President & Director Mr. Mehul Joshi Chief Financial Officer Mr. Geoffrey Beran Rose Chief Commercial Officer Mr. Sri Radhakrishnan Chief Technical Officer Ms. Marcee M. Maroney Vice President of Marketing Ms. Lisa Paul Chief People Officer Mr. Jérôme Erath Senior Vice President & GM of Europe Middle-East & Africa